Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:00
06/23/20
06/23
09:00
06/23/20
09:00
TBIO

Translate Bio

$16.23 /

+0.72 (+4.64%)

, APYX

Apyx Medical

$4.76 /

+0.1 (+2.15%)

, MYOV

Myovant Sciences

$17.38 /

+0.73 (+4.38%)

, SBUX

Starbucks

$75.40 /

+0.01 (+0.01%)

, NRZ

New Residential

$7.41 /

-0.04 (-0.54%)

, XAIR

Beyond Air

$7.69 /

+0.31 (+4.20%)

, WTI

W&T Offshore

$2.56 /

-0.01 (-0.39%)

, IVR

Invesco Mortgage

$4.46 /

+0.135 (+3.12%)

, AAL

American Airlines

$14.91 /

-1.085 (-6.78%)

, SPR

Spirit AeroSystems

$27.22 /

+0.06 (+0.22%)

, CBOE

Cboe Global Markets

$100.04 /

+0.94 (+0.95%)

, MU

Micron

$51.13 /

+0.31 (+0.61%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
XAIR Beyond Air
$7.69 /

+0.31 (+4.20%)

WTI W&T Offshore
$2.56 /

-0.01 (-0.39%)

TBIO Translate Bio
$16.23 /

+0.72 (+4.64%)

SPR Spirit AeroSystems
$27.22 /

+0.06 (+0.22%)

SBUX Starbucks
$75.40 /

+0.01 (+0.01%)

NRZ New Residential
$7.41 /

-0.04 (-0.54%)

MYOV Myovant Sciences
$17.38 /

+0.73 (+4.38%)

MU Micron
$51.13 /

+0.31 (+0.61%)

IVR Invesco Mortgage
$4.46 /

+0.135 (+3.12%)

CBOE Cboe Global Markets
$100.04 /

+0.94 (+0.95%)

APYX Apyx Medical
$4.76 /

+0.1 (+2.15%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

TBIO Translate Bio
$16.23 /

+0.72 (+4.64%)

03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
07/22/19 Jefferies
Translate Bio initiated with a Buy at Jefferies
APYX Apyx Medical
$4.76 /

+0.1 (+2.15%)

06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
MYOV Myovant Sciences
$17.38 /

+0.73 (+4.38%)

06/22/20 JMP Securities
JMP says Myovant's priority review reinforces strength of relugolix data
06/02/20 Citi
Myovant Sciences price target raised to $20 from $9 at Citi
06/01/20 Evercore ISI
Evercore ups Myovant price target to $35, says may still be conservative
06/01/20 JPMorgan
Myovant Sciences price target raised to $26 from $19 at JPMorgan
SBUX Starbucks
$75.40 /

+0.01 (+0.01%)

06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 BMO Capital
Starbucks update confirms expectation of prolonged recovery, says BMO Capital
NRZ New Residential
$7.41 /

-0.04 (-0.54%)

06/12/20 JMP Securities
New Residential price target lowered to $9.50 from $17 at JMP Securities
04/08/20 B. Riley FBR
Cherry Hill Mortgage price target lowered to $9 from $15 at B. Riley FBR
04/06/20 Raymond James
Raymond James cuts estimates and targets for residential mortgage REITs
04/02/20 BTIG
New Residential price target lowered to $10.50 from $18 at BTIG
XAIR Beyond Air
$7.69 /

+0.31 (+4.20%)

10/21/19 Oppenheimer
Oppenheimer starts Beyond Air with Outperform rating, $9 price target
10/21/19 Oppenheimer
Beyond Air initiated with an Outperform at Oppenheimer
WTI W&T Offshore
$2.56 /

-0.01 (-0.39%)

04/17/20 Roth Capital
W&T Offshore upgraded to Buy from Neutral at Roth Capital
03/13/20 Roth Capital
W&T Offshore downgraded to Neutral from Buy at Roth Capital
03/09/20 Stifel
W&T Offshore downgraded to Hold from Buy at Stifel
IVR Invesco Mortgage
$4.46 /

+0.135 (+3.12%)

06/09/20 Barclays
Invesco Mortgage price target raised to $4 from $2 at Barclays
05/27/20 Barclays
Invesco Mortgage downgraded to Underweight on book value erosion at Barclays
05/27/20 Barclays
Invesco Mortgage downgraded to Underweight from Equal Weight at Barclays
05/26/20 Credit Suisse
Invesco Mortgage downgraded to Underperform from Neutral at Credit Suisse
AAL American Airlines
$14.91 /

-1.085 (-6.78%)

06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
SPR Spirit AeroSystems
$27.22 /

+0.06 (+0.22%)

06/23/20 Berenberg
Spirit AeroSystems downgraded to Hold from Buy at Berenberg
04/20/20 Citi
Citi downgrades Boeing to Neutral on 'collapsed' aerospace story
04/13/20 BofA
BofA downgrades Spirit AeroSystems to Underperform, slashes price target to $25
04/13/20 BofA
Spirit AeroSystems downgraded to Underperform from Neutral at BofA
CBOE Cboe Global Markets
$100.04 /

+0.94 (+0.95%)

06/23/20 Goldman Sachs
Cboe Global Markets downgraded to Sell from Neutral at Goldman Sachs
06/10/20 BofA
HFCAA could primarily impact Nasdaq, IntercontinentalExchange, says BofA
06/02/20
Fly Intel: Top five analyst downgrades
06/02/20 JPMorgan
JPMorgan downgrades Cboe to Neutral on 'tepid' trading volumes
MU Micron
$51.13 /

+0.31 (+0.61%)

06/23/20 BMO Capital
Micron downgraded to Market Perform from Outperform at BMO Capital
06/19/20 Wells Fargo
Micron price target raised to $65 from $55 at Wells Fargo
06/10/20
Fly Intel: Top five analyst downgrades
06/10/20 Wedbush
Micron downgraded to Neutral on valuation at Wedbush
XAIR Beyond Air
$7.69 /

+0.31 (+4.20%)

WTI W&T Offshore
$2.56 /

-0.01 (-0.39%)

TBIO Translate Bio
$16.23 /

+0.72 (+4.64%)

SPR Spirit AeroSystems
$27.22 /

+0.06 (+0.22%)

SBUX Starbucks
$75.40 /

+0.01 (+0.01%)

NRZ New Residential
$7.41 /

-0.04 (-0.54%)

MYOV Myovant Sciences
$17.38 /

+0.73 (+4.38%)

MU Micron
$51.13 /

+0.31 (+0.61%)

IVR Invesco Mortgage
$4.46 /

+0.135 (+3.12%)

CBOE Cboe Global Markets
$100.04 /

+0.94 (+0.95%)

APYX Apyx Medical
$4.76 /

+0.1 (+2.15%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

  • 23
    Jun
SPR Spirit AeroSystems
$27.22 /

+0.06 (+0.22%)

SBUX Starbucks
$75.40 /

+0.01 (+0.01%)

NRZ New Residential
$7.41 /

-0.04 (-0.54%)

MU Micron
$51.13 /

+0.31 (+0.61%)

CBOE Cboe Global Markets
$100.04 /

+0.94 (+0.95%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

XAIR Beyond Air
$7.69 /

+0.31 (+4.20%)

WTI W&T Offshore
$2.56 /

-0.01 (-0.39%)

SPR Spirit AeroSystems
$27.22 /

+0.06 (+0.22%)

SBUX Starbucks
$75.40 /

+0.01 (+0.01%)

MYOV Myovant Sciences
$17.38 /

+0.73 (+4.38%)

MU Micron
$51.13 /

+0.31 (+0.61%)

IVR Invesco Mortgage
$4.46 /

+0.135 (+3.12%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

XAIR Beyond Air
$7.69 /

+0.31 (+4.20%)

WTI W&T Offshore
$2.56 /

-0.01 (-0.39%)

TBIO Translate Bio
$16.23 /

+0.72 (+4.64%)

SPR Spirit AeroSystems
$27.22 /

+0.06 (+0.22%)

SBUX Starbucks
$75.40 /

+0.01 (+0.01%)

NRZ New Residential
$7.41 /

-0.04 (-0.54%)

MU Micron
$51.13 /

+0.31 (+0.61%)

IVR Invesco Mortgage
$4.46 /

+0.135 (+3.12%)

CBOE Cboe Global Markets
$100.04 /

+0.94 (+0.95%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

Recommendations
Apyx Medical's expanded international sale 'important', says Piper Sandler » 19:14
06/22/20
06/22
19:14
06/22/20
19:14
APYX

Apyx Medical

$4.76 /

+0.1 (+2.15%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien keeps his Overweight rating and $7 price target on Apyx Medical after its update announcing clearance to sell is J-Plasma in 5 new countries earlier today. The analyst says the approval represents an "important step" for building out the company's international customer base and should contribute a "nice chunk" of growth in the coming years. O'Brien adds that Apyx Medical shares are still down significantly year-to-date, but he sees the company remaining in sound shape financially and expects shares to recover as the pandemic begins to subside.

ShowHide Related Items >><<
APYX Apyx Medical
$4.76 /

+0.1 (+2.15%)

APYX Apyx Medical
$4.76 /

+0.1 (+2.15%)

03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
APYX Apyx Medical
$4.76 /

+0.1 (+2.15%)

Hot Stocks
Apyx Medical approved to sell Helium Plasma products in 5 new countries » 16:07
06/22/20
06/22
16:07
06/22/20
16:07
APYX

Apyx Medical

$4.76 /

+0.1001 (+2.15%)

Apyx Medical announced…

Apyx Medical announced that the company has obtained regulatory approval to market and sell its Helium Plasma Technology products in five new countries: Australia, Brazil, Israel, Taiwan and Thailand. The company has contracted with distributors to market and sell its products in each country. "We are very pleased to obtain regulatory approvals to market and sell our Helium Plasma Technology products in these five new countries." said Charlie Goodwin, President and Chief Executive Officer. "We have been focused on pursuing regulatory clearances in international markets as one of our key strategic priorities to enhance Apyx Medical's long-term growth profile. This strategy is based on the prudent expansion of our commercial footprint outside the U.S. by securing the requisite product registrations for our Helium Plasma Technology products, and identifying strong distribution partners in each respective market. While we expect each of these new countries to contribute to our growth profile in the coming years, we are especially excited by the growth opportunity we have in Brazil, which is estimated to be the second largest cosmetic surgery market in the world in terms of both the total number of procedures performed and the number of surgeons. We shipped an initial commercial order to our distributor in Brazil in late-June and we expect to ship our initial commercial orders to each of the other new countries over the second half of 2020."

ShowHide Related Items >><<
APYX Apyx Medical
$4.76 /

+0.1001 (+2.15%)

APYX Apyx Medical
$4.76 /

+0.1001 (+2.15%)

03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
APYX Apyx Medical
$4.76 /

+0.1001 (+2.15%)

Over a month ago
Earnings
Apyx Medical not providing FY20 guidance 'at this time' » 07:08
05/11/20
05/11
07:08
05/11/20
07:08
APYX

Apyx Medical

$3.25 /

+0.39 (+13.64%)

"Given the…

"Given the challenges and uncertainties posed by the ongoing global pandemic, Apyx Medical will not be providing full year 2020 financial guidance at this time. Assuming a more normalized business environment prevails at the time of our second quarter results conference call in August, we plan to provide updated expectations at that time."

ShowHide Related Items >><<
APYX Apyx Medical
$3.25 /

+0.39 (+13.64%)

03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
Earnings
Apyx Medical reports Q1 EPS (6c), consensus (25c) » 07:08
05/11/20
05/11
07:08
05/11/20
07:08
APYX

Apyx Medical

$3.25 /

+0.39 (+13.64%)

Reports Q1 revenue $5M,…

Reports Q1 revenue $5M, consensus $5.2M. "We reported first quarter sales results at the low-end of the guidance range we provided on March 16, 2020," said Charlie Goodwin, President and CEO. "While the first quarter revenue performance in our OEM business was in-line with our expectations, our revenue performance in our global Advanced Energy business was impacted significantly by the COVID-19 pandemic. Through the first two months of 2020, our Advanced Energy business was performing well with revenue up more than 30% year-over-year. Beginning in March, demand trends from our cosmetic surgery customers around the world slowed materially as a result of the preventative or protective actions taken by governments in each of our primary international markets. In the U.S., we saw a rapid deterioration in procedure trends over the last two weeks of March as states and cities implemented restrictions on elective procedures and temporary closure of non-essential businesses due to COVID-19. In response to the COVID-19 pandemic we acted quickly to protect the health and safety of our employees, patients, surgeon customers and international distributor partners around the world. We have instituted protocols intended to reduce the risk to our manufacturing employees and their families and all non-essential employees are working remotely. We have also taken preemptive steps to curtail spending, including implementing hiring restrictions, reducing most discretionary spending, reducing capital expenditures, and delaying certain R&D projects and clinical research studies. I am proud of the resolve our organization has demonstrated during these incredibly challenging times and appreciate their continued efforts to support our customers and ensure business continuity." Mr. Goodwin continued: "We continue to monitor the crisis caused by COVID-19 in our primary markets and, to date, the impacts of the containment efforts and the restrictions on elective procedures have had a significant impact on our global Advanced Energy sales. There is a significant amount of uncertainty as to when these actions will be lifted, and when patients will choose to undergo elective cosmetic procedures once our customers' practices are allowed to re- open. In the interim, we have a strong balance sheet with more than $51 million in cash at quarter-end and targeted plans to reduce near-term spending in this period of business disruption that together will allow the organization to continue to build on the progress we have made in recent years to enhance this Company's foundation for future growth. We have built a great team at Apyx Medical and we are intently focused on ensuring we are well positioned to return to executing on our growth strategy to expand our share global cosmetic surgery market as soon as the post-COVID recovery begins."

ShowHide Related Items >><<
APYX Apyx Medical
$3.25 /

+0.39 (+13.64%)

03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
Over a quarter ago
Recommendations
Apyx Medical price target lowered to $7 from $10 at Piper Sandler » 05:34
03/17/20
03/17
05:34
03/17/20
05:34
APYX

Apyx Medical

$4.50 /

-1 (-18.18%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Apyx Medical to $7 from $10 and keeps an Overweight rating on the shares. The company's guidance for Q1 was much lower than expected and the outlook for the remainder of 2020 was removed both due to the effect of the coronavirus, O'Brien tells investors in a research note. The analyst anticipates Apyx's business will be "quite soft" in Q2 and Q3 as a result of the virus but that a return to significant growth is in store "on the other side of the outbreak."

ShowHide Related Items >><<
APYX Apyx Medical
$4.50 /

-1 (-18.18%)

01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
05/08/19 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
04/02/19 JMP Securities
Apyx Medical price target lowered to $8 from $12 at JMP Securities
Hot Stocks
Apyx Medical to restate previously issued financial statements » 16:07
03/16/20
03/16
16:07
03/16/20
16:07
APYX

Apyx Medical

$4.50 /

-1 (-18.18%)

Apyx Medical announced it…

Apyx Medical announced it will be restating its previously issued consolidated financial statements for the twelve months ended December, 31 2018 and the quarterly statements for the three and nine months ended September 30, 2018 and three months ended March 31, 2019. This decision was approved by the Company's Board of Directors upon the recommendation of the Company's Audit Committee, and after consultation with Management and the Company's predecessor independent registered public accounting firm. Investors should no longer rely upon the Company's previously released financial statements for the time periods cited above. Similarly, related press releases, earnings releases, and investor communications describing the Company's financial statements for these periods should no longer be relied upon. The decision to restate these financial statements is based on the conclusion that the financial statements for the aforementioned financial periods cannot be relied upon as a result of the aggregation of errors identified by management and the Company's new accounting personnel during the preparation of its fiscal year 2019 Form 10-K and third quarter 2019 Form 10-Q.

ShowHide Related Items >><<
APYX Apyx Medical
$4.50 /

-1 (-18.18%)

01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
05/08/19 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
04/02/19 JMP Securities
Apyx Medical price target lowered to $8 from $12 at JMP Securities
Earnings
Apyx sees Q1 revenue $5M-$5.6M, consensus $7.82M » 16:07
03/16/20
03/16
16:07
03/16/20
16:07
APYX

Apyx Medical

$4.47 /

-1.03 (-18.73%)

Sees Q1 adjusted EBITDA…

Sees Q1 adjusted EBITDA ($7.8M)-($7.4M).

ShowHide Related Items >><<
APYX Apyx Medical
$4.47 /

-1.03 (-18.73%)

01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
05/08/19 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
04/02/19 JMP Securities
Apyx Medical price target lowered to $8 from $12 at JMP Securities
Earnings
Apyx reports Q4 EPS (16c), consensus (19c) » 16:06
03/16/20
03/16
16:06
03/16/20
16:06
APYX

Apyx Medical

$4.47 /

-1.03 (-18.73%)

Reports Q4 revenue…

Reports Q4 revenue $8.38M, consensus $7.86M. "We are excited to bring 2019 to a strong close, with revenue growth of 58% in our Advanced Energy business during the fourth quarter, which was fueled by high demand for our Helium Plasma Technology products from customers in the U.S. cosmetic surgery market as well as our international distributors," said Charlie Goodwin, President and Chief Executive Officer. "In addition to our impressive fourth quarter sales performance, we were also pleased to announce the initiation of enrollment in two new clinical studies evaluating use of our Renuvion technology in dermal resurfacing procedures and skin laxity procedures during the fourth quarter, which represent important milestones in our journey to obtain new clinical indications for specific cosmetic surgery procedures."

ShowHide Related Items >><<
APYX Apyx Medical
$4.47 /

-1.03 (-18.73%)

01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
05/08/19 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
04/02/19 JMP Securities
Apyx Medical price target lowered to $8 from $12 at JMP Securities
Conference/Events
Apyx Medical management to meet with Craig-Hallum » 04:55
01/14/20
01/14
04:55
01/14/20
04:55
APYX

Apyx Medical

$8.20 /

+0.16 (+1.99%)

Meeting to be held in San…

Meeting to be held in San Francisco, CA on January 14 hosted by Craig-Hallum.

ShowHide Related Items >><<
APYX Apyx Medical
$8.20 /

+0.16 (+1.99%)

01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
11/11/19 Piper Sandler
Apyx Medical price target raised to $10 from $8 at Piper Jaffray
05/08/19 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
04/02/19 JMP Securities
Apyx Medical price target lowered to $8 from $12 at JMP Securities

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.